iPS-cell derived dendritic cells and macrophages for cancer therapy.
Antibody-based anti-cancer immunotherapy was recently recognized as one of the truly effective therapies for cancer patients. Antibodies against cell surface cancer antigens, such as CD20, and also those against immune-inhibitory molecules called "immune checkpoint blockers", such as CTLA4 or PD1, have emerged. Large-scale clinical trials have confirmed that, in some cases, antibody-based drugs are superior to conventional chemotherapeutic agents. These antibody-based drugs are now being manufactured employing a mass-production system by pharmaceutical companies. Anti-cancer therapy by immune cells, i.e. cell-based immunotherapy, is expected to be more effective than antibody therapy, because immune cells can recognize, infiltrate, and act in cancer tissues more directly than antibodies. In order to achieve cell-based anti-cancer immunotherapy, it is necessary to develop manufacturing systems for mass-production of immune cells. Our group has been studying immunotherapy with myeloid cells derived from ES cells or iPS cells. These pluripotent stem cells can be readily propagated under constant culture conditions, with expansion into a large quantity. We consider these stem cells to be the most suitable cellular source for mass-production of immune cells. This review introduces our studies on anti-cancer therapy with iPS cell-derived dendritic cells and iPS cell-derived macrophages.
Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University.
Satoru
S
Senju
D000818:Animals; D002471:Cell Transformation, Neoplastic; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D008264:Macrophages / Q000166:cytology / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*